Several new weight loss medicines are making progress in clinical trials, and some are already attracting attention. But there is a difference between a promising trial result and a medicine that you can actually get prescribed. As a pharmacist, I want to explain what is genuinely happening, which treatments are getting closer to approval, and where the safety risks lie. If you are considering options already available, such as Mounjaro, I will cover those too.

What New Weight Loss Drugs Are Coming To The UK?

Several experimental new weight loss drugs in the UK are progressing through clinical development, although none of the three main candidates discussed here has UK marketing authorisation yet. Recent arrivals such as Wegovy tablets and Foundayo show that new treatments are reaching patients, with both oral medicines approved by the MHRA in 2026 and available privately.

The next medicines to watch are retatrutide, CagriSema and survodutide. All three are still experimental, and although their trial results have attracted interest, there is no confirmed UK launch date for any of them. I would suggest being cautious about articles promising that these treatments will arrive by a particular date, as approval can take longer than expected.

What Is Retatrutide, And When Will It Be Approved In The UK?

Retatrutide is an experimental weekly injection from Eli Lilly that targets three hormone receptors: GLP-1, GIP and glucagon. In the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, participants lost an average of up to 20.8% and 22.6% of their body weight, respectively, over 80 weeks. Eli Lilly plans to submit retatrutide to the US regulator in the first quarter of 2027, but no UK filing date has been announced. UK approval timelines remain uncertain, and NHS access would require a separate NICE appraisal.

Important: retatrutide is not legally available in the UK at any price. The MHRA says any product sold outside a clinical trial that claims to contain retatrutide is likely illegal and potentially dangerous. Its Criminal Enforcement Unit has raided several illegal manufacturing sites since October 2025, seizing thousands of unlicensed retatrutide and tirzepatide pens. These products are not tested, not regulated and may not even contain what the label claims.

What About CagriSema And Survodutide?

CagriSema and survodutide are two other experimental treatments worth watching, although neither has confirmed UK approval plans.

CagriSema, developed by Novo Nordisk, combines semaglutide with cagrilintide. Semaglutide acts on GLP-1 receptors, while cagrilintide mimics amylin, a hormone involved in appetite regulation. The combination is designed to reduce appetite through two different pathways. Novo Nordisk submitted CagriSema to the US regulator in December 2025, with a decision expected in late 2026. No UK or European filing has been confirmed.

Survodutide, developed by Boehringer Ingelheim and Zealand Pharma, targets GLP-1 and glucagon receptors. Its phase 3 results, reported in April 2026, showed average weight loss of up to 16.6% at 76 weeks. The companies expect to apply for approval around early 2027.

Both treatments are progressing through development, but trial results alone do not tell us when either medicine will become available in the UK. We will need to see the regulatory decisions and, eventually, how these treatments compare with existing options in clinical practice.

How Do New Weight Loss Drugs Get Approved In The UK?

A medicine needs MHRA marketing authorisation before it can be prescribed here, and that follows large phase 3 trials, not just the promising early results you may read about. The MHRA checks safety, quality and effectiveness, and approval does not happen automatically because a medicine has been approved elsewhere, including in the US. NHS funding is separate again and depends on a NICE appraisal.

So a positive trial result, a company's own filing plan and a product being prescribed somewhere else are each one step among several, not an approval. I would suggest treating "coming soon" articles about unapproved medicines with real caution.

How Might These Compare With Current Options?

Early trial results suggest that retatrutide and survodutide may produce greater average weight loss than some published results for semaglutide. Results at the highest doses also appear broadly comparable with those reported for tirzepatide.

However, these figures need context. The medicines have been studied in different groups of people, over different periods and using different trial methods. There are no direct UK head-to-head comparisons that allow us to rank them fairly. The average results also cannot tell you how much weight you would lose personally.

If you are considering treatment now, rather than waiting for experimental medicines, our guides to Mounjaro vs. Wegovy and how Foundayo differs from Wegovy tablets explain the options available today.

What Should I Do While I Wait?

I would strongly recommend not buying an unlicensed weight loss medicine online, even if the seller describes it as research grade or for research use only. The MHRA has taken action against illegal manufacturing operations involving products sold as retatrutide, and there is no reliable way to check the contents, strength or safety of an unlicensed pen.

If you are looking to lose weight now, there are licensed treatments that may be suitable, depending on your health, medical history and individual circumstances. A consultation with an appropriate prescriber is a safer starting point than trying a medicine that has not been approved.

You can start your online consultation with Pharmacy Planet to discuss currently licensed options and find out whether any may be appropriate for you. In the meantime, I will be keeping an eye on the clinical results and regulatory decisions that could bring new treatments closer to UK patients.

Frequently Asked Questions

Is Retatrutide Available In The UK?

No, not legally. It is still in clinical development, and the MHRA warns that products sold as retatrutide outside a trial are likely illegal and unsafe.

When Will Retatrutide Be Approved In The UK?

Nobody knows for certain. Eli Lilly plans a US filing in early 2027, and UK approval typically follows later, so 2027 or 2028 is a reasonable estimate, not a confirmed date.

Is Retatrutide Stronger Than Mounjaro Or Wegovy?

Early trials suggest greater average weight loss, but there is no UK approved product yet and no direct UK comparison, so please treat this cautiously.

What Is CagriSema?

An experimental combination of semaglutide and cagrilintide from Novo Nordisk. It has been filed with the US regulator, but not yet approved anywhere.

What Is Survodutide?

An experimental injection from Boehringer Ingelheim and Zealand Pharma that combines GLP-1 and glucagon effects. Phase 3 results have been reported, but it is not yet approved.

Can I Buy Any Of These Medicines Early?

No, not legally or safely. Anything sold online as retatrutide, CagriSema or survodutide outside a clinical trial is unlicensed, and the MHRA has prosecuted sellers and seized products.

What Can I Take Now Instead?

Mounjaro, Wegovy injections, Wegovy tablets and Foundayo are currently licensed in the UK. A consultation can tell you whether any is suitable for you.

This article is for general information and is not medical advice. None of the medicines described as in development are licensed in the UK, and none should be bought or used outside an authorised clinical trial. Mounjaro, Wegovy and Foundayo are prescription-only medicines and are supplied only after a clinical assessment.

Sources Referenced

  1. Eli Lilly and Company, Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (23 July 2026)
  2. MHRA, MHRA smashes major illicit weight loss medicine production facility in record seizure (24 October 2025)
  3. MHRA, MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines
  4. Novo Nordisk, press materials on the CagriSema New Drug Application filed with the US FDA (18 December 2025), reported by BioSpace and Chain Drug Review
  5. Boehringer Ingelheim, Survodutide Phase III results presented at ADA 2026, and the SYNCHRONIZE-1 topline announcement (28 April 2026)
  6. MHRA, UK first in Europe to authorise orforglipron (10 August 2026)
  7. Manufacturing Chemist, MHRA approves first oral semaglutide tablet for weight loss in the UK (11 June 2026)